Acumen Pharmaceuticals, Inc. (ABOS) Research

Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.

Market snapshot

Symbol
ABOS
Price
$2.26
Day change
+0.44%
Market cap
$136.9M
P/E ratio
-1.26x
52-week range
1.1-3.6
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$7.00

Peer companies

  • Actuate Therapeutics Inc (ACTU)
  • Agenus Inc. (AGEN)
  • Alector, Inc. (ALEC)
  • Fate Therapeutics, Inc. (FATE)
  • Inovio Pharmaceuticals, Inc. (INO)
  • Opus Genetics, Inc. (IRD)
  • Seres Therapeutics, Inc. (MCRB)
  • Seer, Inc. (SEER)

Recent insider activity

  • Porter Derrell — M-Exempt (6460 shares) on 2026-06-15
  • Porter Derrell — M-Exempt (13040 shares) on 2026-06-17
  • Porter Derrell — S-Sale (6460 shares) on 2026-06-15
  • Porter Derrell — S-Sale (12800 shares) on 2026-06-16
  • Porter Derrell — S-Sale (13040 shares) on 2026-06-17

Open Acumen Pharmaceuticals, Inc. (ABOS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.